What impact does the Centers for Medicare & Medicaid Services drug coverage have on the future of biologic products?

The failure to pass health care reform is not due to partisan politics, but because the Democrats are letting the legislation be written by organized labor and the pharmaceutical companies.

Establishing a pathway for biogeneric competition is an important but challenging task facing lawmakers today.

The evolution of the European Union"s approach to regulating biosimilars is a potential model upon which we can design a process that facilitates access to biosimilars while providing assurances of safety.

Many of the options provided by private health care plans will not exist in a government-run health program.

The political rhetoric surrounding embryonic stem-cell science reveals a widespread misconception of how medical products are created.

Legislation to expose today's biologics to easier competition, after legitimate patents have expired, is going to accelerate development of improved products.

As Congress considers legislation that would allow imitative biological products, known as "biosimilars," to rely on the safety and efficacy data of original innovators, it must ensure that any provisions passed will foster, not stifle, discovery.